BridgeBio's Operating Loss Shrinks To $11.6 Million As Attruby Sales Climb, With Three FDA Dates Ahead

A $75.0 million Bayer milestone and Attruby growth cut the loss; the company has $1.5 billion in cash and FDA dates from November to May.

Share
BridgeBio's Operating Loss Shrinks To $11.6 Million As Attruby Sales Climb, With Three FDA Dates Ahead

BridgeBio Pharma, which develops medicines for genetic diseases, cut its third-quarter loss from operations to $11.6 million, from $145.2 million a year earlier, as sales of its heart drug Attruby grew and Bayer paid a one-time milestone. The company reported the results in an 8-K filed Thursday.

Revenue nearly triples

Total revenue came to $353.2 million, against $120.7 million in the third quarter of 2025. U.S. Attruby net product revenue was $253.2 million, up about $31 million from the prior quarter and about $145 million from a year earlier. Royalty revenue was $20.5 million and license and services revenue was $79.3 million.

The license line includes a one-time $75.0 million sales milestone from Bayer, which sells the drug as Beyonttra in Europe. Without it, the quarter would have looked much less close to break-even.

For the first nine months of 2026, net product revenue was $656.4 million, versus $216.4 million a year earlier. Attruby growth was again led by newly diagnosed, treatment-naïve patients, the company said.

The bottom line is still red. The net loss to common stockholders was $83.0 million, or $0.42 per share, compared with $182.7 million, or $0.95, a year earlier. Operating costs rose to $364.8 million from $265.9 million, with selling, general and administrative expenses up $63.2 million as the company prepares launches.

Cash for three launches

Cash, cash equivalents and marketable securities were $1.5 billion at September 30, against $587.5 million at the end of 2025. The company says that fully funds all three launches and expansion indications.

Attruby is BridgeBio's largest product, a pill for transthyretin amyloid cardiomyopathy, a heart condition. CEO Neil Kumar pointed to real-world comparisons with tafamidis, including an analysis of 2,684 patients that found an 18% lower risk of a composite of death, hospitalization, new atrial fibrillation or diuretic escalation.

Three FDA dates in seven months

All three target dates carry Priority Review:

  • BBP-418 for limb-girdle muscular dystrophy type 2I/R9: November 27, 2026.
  • Oral infigratinib for achondroplasia: February 4, 2027.
  • Encaleret for autosomal dominant hypocalcemia type 1: May 8, 2027.

Kumar said BBP-418 would address a disease with no approved therapy. The company says its field teams are in place, and it has identified more than 600 genetically confirmed encaleret patients, up from about 500 last quarter. European reviews of infigratinib and encaleret are under way, with potential EU approval in the second half of 2027.

The first decision, on BBP-418, is due November 27, and new acoramidis data are planned for the American Heart Association's 2026 Scientific Sessions.

Sources

More on BridgeBio Pharma

All BridgeBio Pharma (BBIO) coverage →